clopidogrel has been researched along with selexipag in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Axelsen, LN; Bruderer, S; Perez Ruixo, JJ; Poggesi, I; Rasschaert, F | 1 |
| Hakamata, A; Inui, N; Kamiya, C; Katayama, N; Namiki, N; Odagiri, K; Tanaka, S; Tatsumi, K; Uchida, S; Watanabe, H | 1 |
2 other study(ies) available for clopidogrel and selexipag
| Article | Year |
|---|---|
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects.
Topics: Acetamides; Clopidogrel; Cytochrome P-450 CYP2C8; Drug Interactions; Healthy Volunteers; Humans; Male; Pyrazines | 2021 |
Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers.
Topics: Acetamides; Area Under Curve; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Japan; Pharmaceutical Preparations; Pyrazines | 2021 |